Home Cart Sign in  
Chemical Structure| 541550-19-0 Chemical Structure| 541550-19-0

Structure of Apilimod
CAS No.: 541550-19-0

Chemical Structure| 541550-19-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Apilimod (STA 5326) acts as a potent IL-12/IL-23 inhibitor, strongly inhibiting IL-12 with IC50s of 1 nM and 2 nM in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively. It also serves as a potent and highly selective PIKfyve inhibitor.

Synonyms: STA 5326; LAM-002A free base; AIT-101

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Apilimod

CAS No. :541550-19-0
Formula : C23H26N6O2
M.W : 418.49
SMILES Code : CC1=CC(/C=N/NC2=NC(OCCC3=NC=CC=C3)=NC(N4CCOCC4)=C2)=CC=C1
Synonyms :
STA 5326; LAM-002A free base; AIT-101
MDL No. :MFCD09954108

Safety of Apilimod

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Apilimod

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Dendritic cells (DC) 50 nM 4 hours To investigate the effect of Apilimod on dendritic cell antigen presentation and T cell activation. Results showed that Apilimod-treated dendritic cells increased MHC-I and MHC-II expression and enhanced T cell activation. PMC11213953
Primary murine cardiac fibroblasts 100 nM 48 hours Apilimod almost completely abrogated collagen accumulation, reduced pro-fibrotic factors (collagen 1, collagen 3, Tgfβ) and inflaμMatory Il-6 transcript levels. PMC8120213
HeLa cells 100 nM 16 hours Apilimod significantly reduced the cell-surface binding of fluorescent TGFβ, indicating a reduction in the amount of surface available receptors in Apilimod-treated cells. PMC8120213
RAW264.7 cells 75 ng/mL 3 days To investigate the effects of IL-12 and IL-23 on the differentiation of RAW264.7 cells into osteoclasts. Results showed that IL-12 treatment alone reduced the number of TRAP+ osteoclasts, while IL-23 treatment alone promoted osteoclast formation and increased the average cell surface area. The combination of IL-12 and IL-23 also promoted cell proliferation and rescued the inhibitory effect of IL-12 on osteoclast formation. PMC7295061
iPSC-MNs 3 μM Apilimod significantly improved the survival of ATP7AM1311V iMNs under neurotrophic withdrawal conditions PMC9676097
VeroE6 cells 10 µM 2 hours To evaluate the inhibitory effect of Apilimod on SARS-CoV-2 replication, results showed that Apilimod effectively inhibited SARS-CoV-2 replication at nanomolar concentrations. PMC9372968
A549/hACE2 cells 50 nM 2 hours To evaluate the inhibitory effect of Apilimod on SARS-CoV-2 replication, results showed that Apilimod effectively inhibited SARS-CoV-2 replication at nanomolar concentrations. PMC9372968
RM-1 cells 10 nM 24 hours To evaluate the cytotoxicity of Apilimod on RM-1 cells, results showed that Apilimod alone had no significant cytotoxic effect on RM-1 cells PMC11186457
MDCK cells 3.8 to 24.6 µM 3 days To evaluate the inhibitory effect of Apilimod on various influenza strains, results showed that Apilimod effectively inhibited the cytopathic effect induced by influenza viruses PMC10777833
Human nasal epithelium (ALI culture) 0.2 mg/mL 2 days To evaluate the inhibitory effect of Apilimod on H1N1 virus in human nasal epithelium, results showed that Apilimod significantly reduced virus release PMC10777833

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MC38 and B16F10 tumor models Oral 30 µg/kg Three times per week for 30 days To investigate the effect of Apilimod on tumor growth and immune response in vivo. Results showed that Apilimod significantly inhibited tumor growth and increased the proportion of intratumoral IFNγ+ CD8+ T cells. PMC11213953
C57BL6/J mice pressure overload-induced heart failure model intraperitoneal 2.5 mg/kg Every 3 days for 42 days Apilimod reduced myocardial interstitial fibrosis development and prevented left ventricular dysfunction. PMC8120213
Mice Calvarial defect model Oral Daily, for 10 weeks To investigate the effect of Apilimod on calvarial defect repair. Results showed that Apilimod treatment significantly promoted bone formation and increased bone volume and semi-quantitative healing score. PMC7086346
Drosophila Drosophila model expressing ATP7AM1311V oral 50 mg/kg 24 and 4 hours before challenge, followed for 96 hours Apilimod significantly improved the motor deficits in Drosophila expressing ATP7AM1311V PMC9676097
BALB/c laboratory mice COVID-19 mouse model Intraperitoneal injection 2 mg/kg 5 times per week for several weeks To evaluate the therapeutic effect of Apilimod in a COVID-19 mouse model, results showed that Apilimod was unable to mitigate disease-associated weight loss or reduce SARS-CoV-2 titers in lung tissues. PMC9372968
C57BL/6J male mice bone metastasis CRPC mouse model tail vein injection 100 mg/kg/day Once daily for 4 weeks To evaluate the inhibitory effect of Apilimod combined with LNP@PTEN on tumor growth and metastasis, results showed that the combination therapy significantly inhibited tumor growth and metastasis, and extended the survival of mice PMC11186457
Mice Experimental Autoimmune Uveoretinitis (EAU) Oral 100 mg/kg daily for 14 days Oral administration of STA-5326 significantly reduced the severity of EAU and decreased the number of IL-17-producing cells. PMC2592812
BALB/c mice H1N1 PR8 infection model Intranasal administration 5 mg/kg or 20 mg/kg Once daily for 14 days To evaluate the antiviral effect of Apilimod in H1N1-infected mice, results showed that Apilimod significantly reduced viral load and inflammation PMC10777833

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02594384 Lymphoma, Non-Hodgkin; Leukema... More >>i, Chronic Lymphocytic Less << Phase 1 Recruiting December 2019 United States, Alabama ... More >> Clearview Cancer Institute Recruiting Huntsville, Alabama, United States, 35805 Contact: Avitra Bone, RN    256-705-4283    studycoordinator@ccihsv.com    Principal Investigator: Marshall Schreeder, MD          United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States, 32224 Contact: Lisa Melfi    904-953-3320    melfi.lisa@mayo.edu    Principal Investigator: Taimur Sher, MD          United States, Georgia Winship Cancer Institute at Emory University Recruiting Atlanta, Georgia, United States, 30322 Contact: Kaylan Dixon    404-778-4449    kaylan.dixon@emory.edu    Principal Investigator: Jonathan Cohen, MD          United States, Indiana Horizon Oncology Research, Inc. Recruiting Lafayette, Indiana, United States, 47905 Contact: Wael A Harb, MD    765-446-5111    wharb@horizonbioadvance.com    Principal Investigator: Wael A Harb, MD          United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Lauren Ramos    617-643-9607    lramos7@mgh.harvard.edu    Principal Investigator: Jeremy Abramson, MD          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Corinne Parker    507-266-3784    parker.corinne@mayo.edu    Principal Investigator: Stephen Ansell, MD          United States, New York New York University School of Medicine Recruiting New York, New York, United States, 10016 Contact: Ion Marinescu    646-501-7920    Ion.Marinescu@nyumc.org    Principal Investigator: Catherine Diefenbach, MD          Weill Cornell Medical College Recruiting New York, New York, United States, 10021 Contact: Rita Gazivoda    212-746-0702    rig9021@med.cornell.edu    Principal Investigator: Sarah Rutherford, MD          United States, Texas University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Linda Claret    713-792-1044    lcclaret@mdanderson.org    Principal Investigator: Loretta Nastoupil, MD          United States, Virginia Virginia Cancer Specialists Recruiting Fairfax, Virginia, United States, 22031 Contact: VCS Phase 1 Team    703-208-3192    Karin.Choquette@usoncology.com    Principal Investigator: Dipti Patel-Donnelly, MD          United States, Washington Virginia Mason Medical Center Recruiting Seattle, Washington, United States, 98101 Contact: Anas Najjar    206-287-5671    Anas.Najjar@virginiamason.org    Principal Investigator: David Aboulafia, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.39mL

0.48mL

0.24mL

11.95mL

2.39mL

1.19mL

23.90mL

4.78mL

2.39mL

References

 

Historical Records

Categories